膀胱癌诊疗服务质量指标:协作综述
本文通过系统综述现有指南与文献,由专家组提出非肌层浸润性和肌层浸润性膀胱癌的推荐质量指标(QI),涵盖术前、术中、术后各环节。尽管目前缺乏实施这些QI获益的1级证据,但测量这些指标有助于改善和基准化膀胱癌最佳诊疗。
要点
- NMIBC质量指标涵盖术前戒烟咨询与影像、术中TURBT安全清单与再分期、术后辅助治疗与风险分层监测。
- MIBC质量指标包括多学科诊疗、新辅助化疗、根治性膀胱切除手术量与淋巴清扫充分性等。
- 参与临床试验被视为高质量诊疗的重要组成。
核心结论
- 基于现有指南与文献提出NMIBC和MIBC的质量指标集,虽缺乏1级证据,但测量这些指标可帮助改善和基准化膀胱癌诊疗。
研究设计与样本
- 系统综述文献以识别当前最佳管理与潜在质量指标,并由专家组选择推荐的质量指标列表。
主要发现
- NMIBC术前质量指标包括戒烟咨询和初始TURBT前适当影像。
- NMIBC术中质量指标包括抗生素给药、使用清单安全施行TURBT、在适当病例行再分期TURBT并活检前列腺尿道。
- NMIBC术后质量指标包括适当接受围手术期辅助治疗、风险分层监测、以及有指征时(如BCG无应答)适当决定更改治疗。
- MIBC术前质量指标包括多学科诊疗、选择可控尿流改道候选者、接受新辅助顺铂为基础化疗、开始根治性治疗的时间、特定患者考虑三联治疗作为保留膀胱替代、术前造口标记咨询、根治性膀胱切除手术量、加速康复外科方案。
- MIBC术中质量指标包括淋巴清扫充分性、失血量和手术时间;术后质量指标包括前瞻性标准化监测发病率和死亡率、pT2疾病阴性手术切缘、初级治疗后适当监测、适当病例接受辅助顺铂为基础化疗。
关键数值与推荐
- 参与临床试验被强调为指示高质量诊疗的重要组成部分。
临床怎么用
- 所提出的质量指标可用于衡量和基准化膀胱癌诊疗,帮助提供者和患者追求最佳结局。
局限性
- 目前缺乏实施这些质量指标获益的1级证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: There is a lack of accepted consensus on what should constitute appropriate quality-of-care indicators for bladder cancer. OBJECTIVE: To evaluate the optimal management of bladder cancer and propose quality indicators (QIs). EVIDENCE ACQUISITION: A systematic review was performed to identify literature on current optimal management and potential quality indicators for both non-muscle-invasive (NMIBC) and muscle-invasive (MIBC) bladder cancer. A panel of experts was convened to select a recommended list of QIs. EVIDENCE SYNTHESIS: For NMIBC, preoperative QIs include tobacco cessation counselling and appropriate imaging before initial transurethral resection of bladder tumour (TURBT). Intraoperative QIs include administration of antibiotics, proper safe conduct of TURBT using a checklist, and performing restaging TURBT with biopsy of the prostatic urethra in appropriate cases. Postoperative QIs include appropriate receipt of perioperative adjuvant therapy, risk-stratified surveillance, and appropriate decision to change therapy when indicated (eg, bacillus Calmette-Guerin [BCG] unresponsive). For MIBC, preoperative QIs include multidisciplinary care, selection for candidates for continent urinary diversion, receipt of neoadjuvant cisplatin-based chemotherapy, time to commencing radical treatment, consideration of trimodal therapy as a bladder-sparing alternative in select patients, preoperative counselling with stoma marking, surgical volume of radical cystectomy, and enhanced recovery after surgery protocols. Intraoperative QIs include adequacy of lymphadenectomy, blood loss, and operative time. Postoperative QIs include prospective standardised monitoring of morbidity and mortality, negative surgical margins for pT2 disease, appropriate surveillance after primary treatment, and adjuvant cisplatin-based chemotherapy in appropriate cases. Participation in clinical trials was highlighted as an important component indicating high quality of care. CONCLUSIONS: We propose a set of QIs for both NMIBC and MIBC based on established clinical guidelines and the available literature. Although there is currently a lack of level 1 evidence for the benefit of implementing these QIs, we believe that the measurement of these QIs could aid in the improvement and benchmarking of optimal care for bladder cancer. PATIENT SUMMARY: After a systematic review of existing guidelines and literature, a panel of experts has recommended a set of quality indicators that can help providers and patients measure and strive towards optimal outcomes for bladder cancer care.
引用
- Leow JJ, Catto JWF, Efstathiou JA, et al. Quality Indicators for Bladder Cancer Services: A Collaborative Review. Eur Urol. 2019. PMID: 31563501. doi:10.1016/j.eururo.2019.09.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。